Pioglitazone

證據等級: L5

預測適應症: 9 個

Pioglitazone: From Type 2 Diabetes Mellitus to Opsismodysplasia

One-Sentence Summary

Pioglitazone is a thiazolidinedione (PPAR-γ agonist) insulin sensitizer whose established use is in Type 2 Diabetes Mellitus. The TxGNN model's top-ranked prediction is Opsismodysplasia, a rare skeletal dysplasia, but this pairing is currently supported by 0 clinical trials and 0 publications, and the evidence pack itself flags it as likely model noise.

Quick Overview

Item	Content
Original Indication	Type 2 Diabetes Mellitus (established use; not captured in this evidence pack — licensing data is empty)
Predicted New Indication	Opsismodysplasia
TxGNN Prediction Score	99.59%
Evidence Level	L5
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known pharmacology, pioglitazone is a thiazolidinedione that acts as a PPAR-γ agonist, improving insulin sensitivity and beta-cell function; its efficacy in Type 2 Diabetes Mellitus is well established.

Opsismodysplasia, however, is a rare skeletal dysplasia caused by mutations in INPPL1, affecting bone growth and ossification. There is no known mechanistic overlap between the PPAR-γ/insulin-sensitizing pathway and the pathophysiology of this condition. The evidence pack's own rationale for this pairing states that despite the high TxGNN similarity score, no identifiable biological plausibility exists, and the association is most likely model noise rather than a genuine repurposing signal.

Consequently, this specific top-ranked prediction should not be interpreted as a credible repurposing lead. Notably, several lower-ranked predictions in the same batch (localized/centrifugal lipodystrophy, ranks 5–8) have a substantially stronger mechanistic rationale, since PPAR-γ is a well-characterized regulator of adipocyte differentiation and lipid storage — though these too currently lack any clinical trial or literature support.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Pioglitazone is currently not marketed in Finland (0 marketing authorizations on record), so no product-level licensing table is available.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA/Fimea package insert warnings and contraindications are recorded as a Blocking data gap (DG001) in this evidence pack — this must be resolved before any S1 safety evaluation can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (Opsismodysplasia) has no clinical trial or literature support and no plausible mechanistic link — the evidence pack itself characterizes it as likely model noise. Combined with the absence of MOA data, safety data, and Finland market presence, there is currently no basis to advance this candidate.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA/Fimea package insert for warnings/contraindications
Resolve DG002 (High): confirm mechanism of action via DrugBank API
If pursuing repurposing signals from this batch, prioritize the lipodystrophy cluster (ranks 5–8) for targeted literature/trial searches given their stronger PPAR-γ mechanistic rationale, rather than the top-ranked but mechanistically unsupported Opsismodysplasia signal
Note: the 9 literature hits under "pancreatic agenesis" (rank 9) are general T2DM/PPAR-γ reviews, not disease-specific — do not count these as supporting evidence without further screening
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.